Clinical trials: Amyotrophic Lateral Sclerosis, open to volunteers
Amyotrophic Lateral Sclerosis
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease.
- Trial name
- FG-CoALS (NCT06147843)
- Testing
- Blood sample
- Where
- 9 sites in France, Germany
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Limoges
Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
- Trial name
- NCT06609213
- Testing
- Medical Food
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andrea Charvet
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Digital Speech Markers for Monitoring ALS in Spanish Speakers
The goal of this observational study is to learn how speech and breathing change over time in Spanish-speaking individuals with amyotrophic lateral sclerosis (ALS) compared to age- and gender-matched individuals without ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
- Trial name
- NCT07341334
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07743268
- Testing
- nL-TARDB-006
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- n-Lorem Foundation
Amyotrophic Lateral Sclerosis, ALS
Multicenter ALS Imaging Study
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year.
- Trial name
- NCT06735014
- Testing
- Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Minnesota
Amyotrophic Lateral Sclerosis
QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up
Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients.
- Trial name
- PEM-SLA (NCT06284161)
- Testing
- Quadriceps Combined Test
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Amyotrophic Lateral Sclerosis (ALS)
Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis
The goal of this clinical trial is to determine whether lung insufflation capacity (LIC) training can help maintain respiratory function and prolong tracheostomy-free survival in people with amyotrophic lateral sclerosis (ALS).
- Trial name
- LIC-ALS (NCT07257302)
- Testing
- LIC Trainer (Lung Insufflation Capacity Trainer)
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- National Center of Neurology and Psychiatry, Japan
ALS (Amyotrophic Lateral Sclerosis)
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited.
- Trial name
- UNZUELUZON ALS (NCT07737977)
- Testing
- peripheral venous blood collection, collection of medical data related to patient care
- Where
- 2 sites in France, Spain
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis (ALS)
Safety Study of XT-150 in Participants With ALS
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06704347
- Testing
- XT-150
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Xalud Therapeutics, Inc.
ALS, ALS (Amyotrophic Lateral Sclerosis)
Healey ALS MyMatch Common Screening Protocol
The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial.
- Conditions
- ALS, ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
- Trial name
- MCSP (NCT07400393)
- Volunteers
- 500 people
- Sponsor
- Massachusetts General Hospital
Spinal Cord Injury, Amyotrophic Lateral Sclerosis
iBCI Optimization for Veterans With Paralysis
VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis…
- Conditions
- Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome
- Trial name
- NCT05470478
- Testing
- Mobile neural decoding platform (mobile iBCI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- VA Office of Research and Development
Amyotrophic Lateral Sclerosis (ALS), Autoantibody
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Autoantibody, Plasmapheresis
- Trial name
- PALADIN2 (NCT07726563)
- Testing
- plasmapheresis
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Amyotrophic Lateral Sclerosis (ALS)
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using…
- Trial name
- NCT07142291
- Testing
- Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg)
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 105 people
- Sponsor
- PhenoNet, Inc.
Amyotrophic Lateral Sclerosis (ALS)
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality.
- Trial name
- tDCS-ALS (NCT06719947)
- Testing
- Active HD-tDCS, Simulated HD-tDCS
- Where
- 4 sites in Brazil, Chile
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Rio Grande do Norte
Amyotrophic Lateral Sclerosis (ALS), Neurodegenerative Disorders
Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease, often difficult to diagnose due to symptoms similar to other neurological pathologies.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Neurodegenerative Disorders, Motor Neuron Diseases
- Trial name
- DIAGONALS (NCT07706270)
- Testing
- Serum Neurofilament Serum NfL Measurement
- Volunteers
- 138 people
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07703462
- Testing
- nL-TARDB-002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Amyotrophic Lateral Sclerosis
Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
- Trial name
- NCT07095686
- Testing
- nL-CHCHD-001
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- n-Lorem Foundation
Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment.
- Trial name
- SpeechBCI (NCT07698496)
- Testing
- Chronic speech BCI
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects…
- Trial name
- NCT02478450
- Testing
- Q-Cells
- Volunteers
- 30 people
- Sponsor
- Q Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Analysis of Human ALS Tissues and Registry of ALS Patients
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain.
- Trial name
- NCT05067179
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois at Chicago